Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, minerals and dietary supplements, feminine hygiene, diabetes care, scar management, and anti-parasite categories under the Good Sense, Sergeant's, Sentry, Zephrex D, PetArmor, and ScarAway brand names.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone353-1709-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.73 billion
Profitability
Miscellaneous
Employees10,600
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Perrigo (NYSE:PRGO) Frequently Asked Questions
What is Perrigo's stock symbol?
Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."
How often does Perrigo pay dividends? What is the dividend yield for Perrigo?
Perrigo announced a quarterly dividend on Wednesday, July 31st. Shareholders of record on Friday, August 30th will be given a dividend of $0.21 per share on Tuesday, September 17th. This represents a $0.84 annualized dividend and a yield of 1.56%. The ex-dividend date is Thursday, August 29th. View Perrigo's Dividend History.
How were Perrigo's earnings last quarter?
Perrigo Company PLC (NYSE:PRGO) issued its quarterly earnings data on Thursday, August, 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.05. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.13 billion. Perrigo had a return on equity of 9.57% and a net margin of 1.87%. Perrigo's quarterly revenue was down 3.2% compared to the same quarter last year. During the same period last year, the firm posted $1.22 earnings per share. View Perrigo's Earnings History.
When is Perrigo's next earnings date?
What guidance has Perrigo issued on next quarter's earnings?
Perrigo issued an update on its FY19 earnings guidance on Thursday, August, 8th. The company provided earnings per share guidance of $3.75-4.05 for the period, compared to the Thomson Reuters consensus estimate of $3.94.
What price target have analysts set for PRGO?
7 brokers have issued 12 month price targets for Perrigo's stock. Their predictions range from $48.00 to $72.00. On average, they expect Perrigo's share price to reach $56.71 in the next year. This suggests a possible upside of 5.1% from the stock's current price. View Analyst Price Targets for Perrigo.
What is the consensus analysts' recommendation for Perrigo?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo.
Has Perrigo been receiving favorable news coverage?
Press coverage about PRGO stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Perrigo earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Perrigo.
Who are some of Perrigo's key competitors?
Some companies that are related to Perrigo include Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Ionis Pharmaceuticals (IONS) and Teva Pharmaceutical Industries (TEVA).
What other stocks do shareholders of Perrigo own?
Who are Perrigo's key executives?
Perrigo's management team includes the folowing people:
- Mr. Murray S. Kessler, CEO, Pres & Director (Age 59)
- Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)
- Mr. Svend Andersen, Exec. VP & Pres of Consumer Healthcare International (Age 57)
- Mr. Ronald L. Winowiecki, Advisory (Age 53)
Who are Perrigo's major shareholders?
Perrigo's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.54%), State of Alaska Department of Revenue (0.08%), Assenagon Asset Management S.A. (0.01%), CenturyLink Investment Management Co (0.01%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Perrigo stock include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Murray S Kessler, Ronald Winowiecki, Svend Andersen, Theodore R Samuels II, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.
Which major investors are selling Perrigo stock?
PRGO stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, CenturyLink Investment Management Co and Crossmark Global Holdings Inc.. View Insider Buying and Selling for Perrigo.
Which major investors are buying Perrigo stock?
PRGO stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Assenagon Asset Management S.A.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Murray S Kessler, Svend Andersen, Theodore R Samuels II, Todd W Kingma and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.
How do I buy shares of Perrigo?
Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Perrigo's stock price today?
One share of PRGO stock can currently be purchased for approximately $53.96.
How big of a company is Perrigo?
Perrigo has a market capitalization of $7.34 billion and generates $4.73 billion in revenue each year. The company earns $131 million in net income (profit) each year or $4.55 on an earnings per share basis. Perrigo employs 10,600 workers across the globe.View Additional Information About Perrigo.
What is Perrigo's official website?
How can I contact Perrigo?
Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]
MarketBeat Community Rating for Perrigo (NYSE PRGO)
MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
